CTOs on the Move


 
  • Number of Employees:
  • Annual Revenue:

  • ,

Executives

Name Title Contact Details

Similar Companies

Mercedes-Benz of Henderson

Established in 1946 as well as being family owned and operated since 1946, the Fletcher Jones Company has grown into one of the largest and most respected automotive groups in the world. Our Preferred Owner Benefits include many amenities such as a complimentary Mercedes-Benz courtesy vehicle and a complimentary hand car wash.

XLI Manufacturing, LLC

XLI is a full service manufacturer of precision engineered mechanical components and complex electro-mechanical subassemblies for applications including motorized vehicles, firearms, security instrumentation and communications. XLI manufactures your product according to your specifications and delivery requirements on a repetitive, low volume production basis in our U. S. facilities. Our organization provides complete customer support from engineering to manufacturing to product testing, packaging and delivery to streamline your procurement effort and expense.

Axtra3D

Axtra3D brings first-of-its-kind functionality to 3D printing with innovative products that are revolutionizing Additive Manufacturing. Outperforming SLA, DLP & LCD in speed, resolution, print area and surface quality, Axtra3Ds Lumia 3D Printer delivers a whole new 3D Printing experience with reliable, scalable, high speed, fine resolution printing—all in one machine.

IMUNON

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.